Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Sanofi Consumer Healthcare India EV-to-EBITDA?
Sanofi Consumer Healthcare IndiaNSE:SANOFICONR +0.99%24 EV-to-EBITDA is 24.15 as of Sep. 11, 2026, which is 37% below its 10-year median of 38.43. GuruFocus rates NSE:SANOFICONR with a GF Score™ of 24/100. The stock has 2 warning signs investors should review. Among 727 Drug Manufacturers companies, Sanofi Consumer Healthcare India ranks worse than 74% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Sanofi Consumer Healthcare India's enterprise value is ₹89,927 Mil.
Sanofi Consumer Healthcare India's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was ₹3,724 Mil. Therefore, Sanofi Consumer Healthcare India's EV-to-EBITDA for today is 24.15.
The historical rank and industry rank for Sanofi Consumer Healthcare India's EV-to-EBITDA or its related term are showing as below:
NSE:SANOFICONR'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 23.78 Med: 38.43 Max: 50.68
Current: 24.15
During the past 3 years, the highest EV-to-EBITDA of Sanofi Consumer Healthcare India was 50.68. The lowest was 23.78. And the median was 38.43.
NSE:SANOFICONR's EV-to-EBITDA is ranked worse than 74% of 727
companies
in the Drug Manufacturers industry
Industry Median: 13.34
vs NSE:SANOFICONR: 24.15
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Sanofi Consumer Healthcare India (NSE:SANOFICONR) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sanofi Consumer Healthcare India's PE Ratio (TTM) for today is calculated as:
Sanofi Consumer Healthcare India's share price for today is ₹4089.60.
Sanofi Consumer Healthcare India's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹115.490.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sanofi Consumer Healthcare India EV-to-EBITDA Chart
NSE:SANOFICONR vs LLY, JNJ, ABBV: EV-to-EBITDA Comparison
For the Drug Manufacturers - General subindustry, Sanofi Consumer Healthcare India's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sanofi Consumer Healthcare India EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sanofi Consumer Healthcare India's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Sanofi Consumer Healthcare India's EV-to-EBITDA falls into.
Sanofi Consumer Healthcare India's current Enterprise Value is ₹89,927 Mil.
Sanofi Consumer Healthcare India's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹3,724 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sanofi Consumer Healthcare India (NSE:SANOFICONR) has a EV-to-EBITDA of 24.15 as of Sep. 11, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Sanofi Consumer Healthcare India. This is 37% below median its historical median of 38.43. Over the past decade, Sanofi Consumer Healthcare India's EV-to-EBITDA has ranged from 23.78 to 50.68. According to the industry distribution chart, Sanofi Consumer Healthcare India ranks #538 out of 727 companies in the Drug Manufacturers industry, placing it in the top 74%.
Is Sanofi Consumer Healthcare India's EV-to-EBITDA too high?
Sanofi Consumer Healthcare India's current EV-to-EBITDA of 24.15 is 37% below median its 10-year median of 38.43. Over the past 10 years, this metric has ranged from a low of 23.78 to a high of 50.68. The Drug Manufacturers industry median EV-to-EBITDA is 13.34. Sanofi Consumer Healthcare India's value of 24.15 is 81% above this industry median. Based on the distribution chart, Sanofi Consumer Healthcare India ranks #538 out of 727 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Sanofi Consumer Healthcare India has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Sanofi Consumer Healthcare India's EV-to-EBITDA compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Sanofi Consumer Healthcare India ranks #538 out of 727 companies for EV-to-EBITDA. This places Sanofi Consumer Healthcare India in the lower half of its industry. The industry median EV-to-EBITDA is 13.34. Sanofi Consumer Healthcare India's value of 24.15 is 81% above this benchmark. Historically, Sanofi Consumer Healthcare India's own EV-to-EBITDA has ranged from 23.78 to 50.68 over the past decade. While the company's 10-year median is 38.43 vs. the industry median of 13.34, Sanofi Consumer Healthcare India has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.34, based on 727 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sanofi Consumer Healthcare India's current EV-to-EBITDA of 24.15 is 81% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Sanofi Consumer Healthcare India. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sanofi Consumer Healthcare India's current EV-to-EBITDA is 24.15, which is 37% below median its own 10-year median of 38.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanofi Consumer Healthcare India stock overvalued right now?
Sanofi Consumer Healthcare India (NSE:SANOFICONR) has a current EV-to-EBITDA of 24.15. The current EV-to-EBITDA is 24.15, which is 37% below median its 10-year median of 38.43 and 81% above the Drug Manufacturers industry median of 13.34. Sanofi Consumer Healthcare India's overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Sanofi Consumer Healthcare India (NSE:SANOFICONR), the current EV-to-EBITDA is 24.15 as of Sep. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sanofi Consumer Healthcare India Ltd is mainly engaged in the business of manufacturing and trading of drugs and pharmaceutical products. The Company also has various independent contract/third-party manufacturers based across the country and provides business support services to its group entity in India. Its products include Allergy Relief (Allegra), Pain Care (Combiflam), and Physical Wellness (DePURA). The Company sells its products in India through independent distributors and outside India. Its operations are limited to one segment, namely Pharmaceutical Business. The Company operates in India, which generates the maximum revenue, and Outside India.
24GF Score
Get the complete analysis for NSE:SANOFICONR
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SANOFICONR has been successfully added to your 
